The next big thing at GlaxoSmithKline R&D is clearly oncology — respiratory can take a back seat now
GlaxoSmithKline is pondering some big new moves on the pharma R&D side of the business. And these suggestions may have caught more than a few GSK staffers by surprise.
Their cancer research chief, Axel Hoos, is telling reporters that the pharma giant is considering exiting the respiratory side of the business — where it was able to make a series of mostly marginal advances with new drugs in recent years — and setting up a research center on the West Coast, close to where R&D chief Hal Barron is based.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
